SUBSCRIBE
SUBSCRIBE
News   Policy

German Merck KGaA Says FDA Seeks More Data On Rebif

February 6, 2007 | 
1 min read
FRANKFURT, Feb 6 (Reuters) - German Merck KGaA said on Tuesday a U.S. regulator has asked for more data on a new formulation of its multiple sclerosis drug Rebif, a move that could delay approval for the drug to come to the market.

>>> Discuss This Story

Regulatory Europe
MORE ON THIS TOPIC
Man jumping, running, and winner holding trophy. Competition, challenge, risk and reward concept. Vector illustration.
IgA nephropathy
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
July 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Two arrow signs representing the new way and old way approach to business
Policy
FDA disavows Makary, Prasad’s papers as lawmaker blasts ‘shoot-from-the-hip’ policymaking
July 17, 2026
 · 
3 min read
 · 
Tristan Manalac
Magnifying Glass Focused on Circuit Board with AI Word, Representing Artificial Intelligence and Technology Innovation.
Manufacturing
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
July 16, 2026
 · 
3 min read
 · 
John Potter
Silhouette of scuba diver, coral reef and underwater cave on a blue sea background. Vector nature illustration. Marine life.
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
July 16, 2026
 · 
2 min read
 · 
Gabrielle Masson